Research Peptide
CJC-1295 No DAC / Ipamorelin 5MG/5MG
$85.00
● In Stock
Single-vial co-formulation pairing CJC-1295 (GHRH analog) with Ipamorelin (selective ghrelin/GHRP agonist) — a widely used research stack for pulsatile GH release, sleep, and recovery studies.
Purity
≥99.4%
Mol. Weight
CJC-1295: 3,367.97 g/mol · Ipamorelin: 711.85 g/mol
Amino Acid Sequence
CJC-1295 (mod. GHRH 1-29) + Ipamorelin (pentapeptide)
Storage
Store lyophilized peptide at -20°C in a sealed vial away from light and moisture. After reconstitution with bacteriostatic water, keep refrigerated at 2–8°C and use within 30 days. Do not freeze reconstituted solution.
Certificate of Analysis
View third-party lab report · LOT #NP-CJC129-26
This co-formulated vial pairs CJC-1295 without DAC (Mod GRF 1-29) with Ipamorelin, delivering 5 mg of each. CJC-1295 is a stabilized GHRH analog with a ~30-minute half-life; Ipamorelin is a selective ghrelin-receptor agonist that releases GH without elevating cortisol or prolactin. Reported research benefits: increased amplitude and frequency of pulsatile GH release; downstream elevation of IGF-1 and IGFBP-3; improved slow-wave and REM sleep architecture; support for lean-mass accrual and fat-mass reduction in body-composition studies; enhanced post-exercise and post-surgical recovery; improved skin elasticity and collagen turnover; and a clean selectivity profile with no measurable rise in prolactin, ACTH, or cortisol.
Related Products
Retatrutide 30MG
Triple agonist — high-dose vial for extended studies.
Retatrutide 50MG
Triple agonist — bulk presentation for long-term protocols.
Tirzepatide 10MG
First-in-class dual GIP / GLP-1 receptor agonist.